



Article

Liver Enzymes' Influence on Hepatic Disorder Diagnosis

Hawraa Hamid Hussein^{*1}, Zainab F. Hassan²

1,2. Department of Physiology, College of Medicine, University of Babylon, Iraq

* Correspondence: med278.hawraa.hamid@uobabylon.edu.iq

Abstract: In order to diagnose and treat liver diseases, liver enzymes are essential. These proteins, known by way of enzymes, aid in the liver's numerous metabolic processes. When liver cells are damaged, these enzymes are released into the bloodstream, which can be detected by blood tests. The levels of liver enzymes can assist reflect the extent of liver damage, the kind of liver disease, and how effectively the liver is functioning. The purpose of the review was to investigate the diagnostic value of Liver Enzymes' in Hepatic Disorder. A thorough analysis of the literature dealing with Liver Enzymes' assays, as well as their clinical effectiveness, sensitivity, specificity, and use in diverse patient populations was performed. The focus of the analysis is on the comparative studies, biomarker performance evaluation, and new diagnostic protocol development. Liver Enzymes' assays enhance the diagnosis of liver diseases by detecting liver enzymes at higher concentrations, which allows for timely intervention and risk stratification. Liver Enzymes' tests have showed considerable challenges like the degree of standardization of the assay. Because it permits more accurate and timely liver disorder notifications, the integration of liver enzymes assays into clinical practice aids in the accurate and timely detection of Liver Enzymes' injury.

Keywords: Prothrombin Time, Risk Stratification, Sensitivity, Alanine Aminotransferase, Lactate Dehydrogenase

Citation: Hussein H. H. and Hassan Z. F. Liver Enzymes' Influence on Hepatic Disorder Diagnosis. Central Asian Journal of Medical and Natural Science 2025, 6(3), 1042-1046.

Received: 21st Apr 2025

Revised: 28th Apr 2025

Accepted: 5th May 2025

Published: 10th May 2025



Copyright: © 2025 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license

(<https://creativecommons.org/licenses/by/4.0/>)

1. Introduction

The pattern as well as degree of raise of these tests, in addition to the overall clinical picture, might give clues to the underlying cause of these problems. Liver enzymes can be classified as markers of liver injury, and levels that are greater or lower than normal can show liver abnormalities, alkaline phosphatase, gamma glutamyl-transferase, alanine and aspartate aminotransferases, and indicators of liver function such as albumin, coagulation factors (prothrombin time/INR, fibrinogen), and bilirubin [1].

Mild elevations (less than two to three times the upper border of normal) that do not cause any symptoms may be observed as benign when a liver enzyme is discovered to be abnormal. It is moreover widely acknowledged aberrant enzymes of liver are associated with "hard end points" in liver disease, including death in addition to transplant requirement, as well as fibrosis progression in addition to hepatocellular carcinoma development [2].

Aminotransferases in Enzyme Activity in Hepatic Disease.

The most sensitive indicators of acute hepatocellular damage are aminotransferases. While AST is current in extrahepatic organs for example the brain, heart, in addition to skeletal muscle [3].

Alanine Aminotransferase(ALT)

ALT is more specific to liver injury due to its highest concentration in the liver. Because transaminases are found in the cytosol, even little changes to the integrity of the hepatocyte cell membrane can cause their instant release. Unfortunately, their diagnostic utility's specificity is limited by indiscriminate leaking. However, serum transaminase activity duration and magnitude, assessed successively, can approximate the extent of hepatocyte involvement and predict disease activity and severity. ALT is secreted into the bloodstream and levels rise when the liver is injured [4].

The SGPT is another name for this test. Hepatocellular necrosis and inflammation cause the most rise in circulating ALT activity. Serum ALT activity rises dramatically within 24 to 48 hours following acute severe hepatocyte necrosis, reaching values that are frequently more than 100 times higher than normal, peaking within the first five days of the damage. Over the course of two to three weeks, ALT activity progressively returns to normal if the harmful incident is resolved. Some severe hepatotoxins do not generate elevated ALT activity because they interfere with ALT production or block gene transcription. A falling ALT, however, may also indicate an acquired scarcity of viable hepatocytes at end-stage state in many acute severe injuries [5].

2. Materials and Methods

According to the article 'Liver Enzymes' Influence on Hepatic Disorder Diagnosis' researchers thoroughly studied published sources through a literature review approach. Researchers examined many published documents to understand how liver enzyme tests help doctors identify specific liver problems. Our criteria for selecting studies looked at scientific papers exploring the role of blood testing enzymes ALT, AST, ALP, GGT, LDH, and others that analyze liver function. Our research team reviewed recent medical literature to investigate how diagnostic testing works with liver enzymes in different medical settings. Our research team focused on studies that compared how enzymes change over time during progressive liver disease. Medical professionals used the R-value test results to determine specific liver injury patterns either hepatocellular or cholestatic. Our research examined how enzyme performance varies across medical records and patient health histories to reveal its accuracy in diagnoses. The method relies on scientific evidence to study how enzymes react to both sudden and lasting liver diseases which helps doctors develop better patient testing systems. Our research method focuses on scientific evidence to show how liver enzymes behave during acute and chronic conditions which helps develop better diagnosis options for medical use. This approach lets researchers dependably detect field weaknesses while showing how to study the subject better and help doctors make better choices.

3. Results and Discussion

An enzyme called AST aids in body's breakdown of amino acids. Alike to ALT, blood levels of AST are frequently low. A rise in AST values could indicate muscle damage, liver illness, or liver damage. SGOT is another name for this test. Many different tissues, particularly muscle, contain significant amounts of AST. Hepatocyte cell membrane permeability alterations, hepatocyte mitochondrial membrane damage, cell necrosis, hepatic inflammation, in addition to other reversible or irreversible conditions can all be reflected by elevated AST activity [6].

Alkaline Phosphatase in Hepatic Disease (ALP)

The liver and bone contain the enzyme ALP, which is crucial for the breakdown of proteins. Liver cells and bone contain about 80% of ALP, while the placenta, ileal mucosa, and kidneys contain lesser levels. Because this enzyme is too originate in bones, elevated levels of ALP may indicate liver disease or damage, such as a blocked bile duct, or specific bone disorders. ALP levels may increase in cholestasis or hepatocellular damage due to increased enzyme production [7].

Gamma-glutamyltransferase and lactate dehydrogenase

Elevated levels of GTT could indicate damage the liver or bile ducts. In addition to liver disease, other factors may cause this nonspecific test to be raised. Typical testing for liver function include. The liver contains the enzyme LD. Elevated amounts could indicate liver injury. Higher levels of LD, however, can also be brought on by other situations. The liver is one of the many bodily tissues that contain lactate dehydrogenase (LDH). Liver injury may be indicated by elevated LDH levels [8].

The most prevalent protein in plasma, which is only produced by hepatocytes and accounts for over half of its total protein composition. Because of the half-life of albumin, a decrease in albumin usually signifies liver illness that lasts for at least two to three weeks. This is also a non-specific indicator of liver function because it can also decrease in cases of inflammation, nephrotic syndrome, fluid overload, or starvation [9].

Coagulation test

represent the pathway of extrinsic coagulation. Since the liver produces several clotting factors (except for factor VIII), PT elevation may be impacted within 24 hours after the onset of liver disease and can be a sign of deficits linked to severe hepatic dysfunction. Disseminated intravascular coagulation, vitamin K insufficiency, and certain anticoagulants can also cause PT to be prolonged. Crucially, in patients with cirrhosis, PT is not a good predictor of bleeding risk [10].

Because factor VII has the shortest half-life (2–6 hours) of all the coagulation factors evaluated in the international normalized ratio (INR), This test is also termed "ProTime INR" and "INR PT" (13). They are used to test vitamin K status, liver damage, and warfarin dosage in addition to determining the blood's propensity to clot it can be utilized as a marker of hepatic synthetic function in patients with liver disease. However, as the INR .More recent diagnostics, such thromboelastograms (TEG) and thromboelastometry (ROTEM), are superior at determining coagulation in liver patients [11].

Bilirubin

There are two types of bilirubin: conjugated and unconjugated. The primary cause of unconjugated bilirubin, which is linked to albumin in plasma, is hemoglobin degradation in senescent blood cells. Before being expelled into the gut and gone as feces, it is taken to the liver, where it gets conjugated [12].

Bilirubin metabolism is intimately related to the liver's capacity to conjugate and eliminate chemicals, even though it is not a direct indicator of liver function. Therefore, compared to indirect bilirubinemia, which can be caused by various extrahepatic problems such hemolysis, direct bilirubinemia may be more indicative of liver function. The failure of red blood cells results in the manufacture of bilirubin. Bilirubin is eliminated in feces after passing through liver. Elevated bilirubin levels may indicate illness before damage to the liver. Occasionally, diseases like liver duct obstruction or specific forms of anemia can also result in increased bilirubin levels [13].

5' Nucleotidase

A glycoprotein called 5' Nucleotidase is present in the cytoplasmic membrane of every cell in the body and catalyzes the transformation of nucleoside-5-phosphate into inorganic phosphates. Obstructiv Conditions include obstructive jaundice, parenchymal liver disease, liver metastases, and bone cause its level to rise. During pregnancy's second and third trimesters, serum NT levels are greater [14].

Ceruloplasmin

The liver produces the acute phase protein ceruloplasmin. It is the copper ion's carrier. Pregnancy, infections, non-Wilson liver disease, in addition to obstructive jaundice all raise its level. When ceruloplasmin levels are low in Wilson disease, copper builds up in bodily tissues [15].

Alpha-fetoprotein

In the fetal liver, alpha-fetoprotein (AFP) is highly expressed. It is unclear exactly what mechanism caused adults' AFP synthesis to be suppressed. An increase in AFP may

result from childhood liver maturation arrest and exposure to carcinogens. AFP levels in hepatocellular carcinoma might reach 400–500 µg/L [16].

Alkaline phosphatase (ALP) and aminotransferase (ALT) levels are compared to their upper normal limits to determine the R-value, a scoring tool for identifying patterns of liver injury ($R = (ALT \div ULN\ ALT) / (ALP \div ULN\ ALP)$). Liver injury patterns can be branded as mixed, cholestatic, or hepatocellular based on the R-value. Please be aware that this specific tool does not include bilirubin [17].

1-Hepatocellular pattern: The underlying cause of hepatocellular injury determines the extent of AST and ALT rise. The AST/ALT ratio also offers diagnostic hints; in alcohol-associated liver illness, over 90% of patients have an AST/ALT ratio >2, most likely as a result of alcohol-induced pyridoxal phosphate depletion, which is necessary for ALT synthesis, and mitochondrial AST release from alcohol-mediated damage. Although it is less noticeable than in alcohol-associated liver disease, elevated AST > ALT can also occur in cirrhosis of any origin [18].

2) Cholestatic pattern: This usually denotes bile duct pathology, and further imaging or testing is frequently necessary to identify the underlying reason. There are two types of cholestatic liver diseases: extrahepatic and intrahepatic [19].

3) Mixed pattern: Contains elements of both the hepatocellular and cholestatic patterns of damage. Depending on the offending substance, drug-induced liver injury (DILI) can manifest as any pattern of injury, including a mixed pattern. As synthetic function deteriorates and a patient develops jaundice from hyperbilirubinemia, some liver injuries may begin as more hepatocellular and eventually become mixed [20].

4. Conclusion

Elevated ALP, with or without bilirubin increase, is a common symptom of cholestatic liver disease. To determine the cause, isolated ALP elevation requires GGT testing. By checking for biliary duct dilatation, an abdomen ultrasonography can assist in distinguishing between extrahepatic and intrahepatic cholestatic illness. While suspected intrahepatic reasons call for additional serology to check for autoimmune hepatitis, primary sclerosing cholangitis, or primary hepatitis, extrahepatic causes might need additional imaging with MRCP or ERCP.

REFERENCES

- [1] G. MR и S. J, «Alkaline phosphatase», *Cold Spring Harb Protoc*, т. 2020, вып. 8, с. 100768, 2020.
- [2] Z. MG, F. M, C. DB, и et al, «Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis», *JHEP Rep*, т. 2, вып. 4, с. 100120, 2020.
- [3] P. S и др., «Coagulation profile in liver diseases: A study of 250 cases in a tertiary care hospital», *Int J Clin Diagn Pathol*, т. 3, вып. 3, сс. 185–188, 2020, doi: 10.33545/pathol.2020.v3.i3c.280.
- [4] I. Dolz Pérez и et al, «Development of polypeptide-based therapeutics for topical delivery». 2019 г.
- [5] F. H, K. T, F. T, и et al, «Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study», *BMC Gastroenterol*, т. 20, вып. 1, сс. 1–9, 2020.
- [6] W. S, A. J, D. G, и G. AL, «Marked increase of gamma-glutamyltransferase as an indicator of drug-induced liver injury in patients without conventional diagnostic criteria of acute liver injury», *Visc Med*, т. 38, вып. 3, сс. 223–228, 2022.
- [7] R. F, «Optical immunoassays methods in protein analysis: an overview», *Chemosensors*, т. 10, с. 326, 2022, doi: 10.3390/chemosensors10080326.
- [8] Z. DM, E.-G. MI, O. HA, и et al, «Recent advances with alkaline phosphatase isoenzymes and their inhibitors», *Arch Pharm Weinh.*, т. 353, вып. 5, с. e2000011, 2020.
- [9] S. S, P. D, W. R, и et al, «Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments», *PLoS One*, т. 15, вып. 5, с. e0229753, 2020.
- [10] K. HR и H. MA, «Association between serum liver enzymes and metabolic syndrome in Korean adults», *Int J Env. Res Public Health*, т. 15, с. 1658, 2018.

- [11] C. N и др., «The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases», *Hepatology*, т. 67, cc. 328–357, 2018, doi: 10.1002/hep.29367.
- [12] D. AR, I. DK, и J. Z, «Bile metabolism and lithogenesis: an update», *Surg Clin*, т. 99, вып. 2, cc. 215–229, 2019.
- [13] Z. H и др., «Utility of liver function tests in acute cholecystitis», *Ann Hepatobiliary Pancreat Surg*, т. 23, cc. 219–227, 2019, doi: 10.14701/ahbps.2019.23.3.219.
- [14] K. TP, K. V, и P. B, «A study of coagulation profile in diseases of liver: at tertiary care center hospital», *Indian J Pathol Oncol*, т. 6, вып. 1, cc. 107–111, 2019.
- [15] S. T, L. Y, S. J, и et al, «Incidence and etiology of drug-induced liver injury in mainland China», *Gastroenterology*, т. 156, вып. 8, cc. 2230–2241.e11, 2019.
- [16] M. M, P. R, P. V, и et al, «Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease», *Aliment Pharmacol Ther*, т. 48, cc. 1117–1127, 2018.
- [17] K. P и др., «Serum liver enzymes and metabolic syndrome from the Rafsanjan Cohort Study», *J Invest Med*, т. 71, cc. 140–148, 2023.
- [18] S. MG, «The global epidemic of the metabolic syndrome», *Curr Hypertens Rep*, т. 20, cc. 1–8, 2018.
- [19] A. D, G. S, и V.-B. R, «Tissue non-specific alkaline phosphatase and vascular calcification: a potential therapeutic target», *Curr Cardiol Rev*, т. 15, вып. 2, cc. 91–95, 2019.
- [20] T. NA, L. ASF, M. BJ, и et al, «Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance», *Hepatology*, т. 67, cc. 1560–1599, 2018.